Spero Therapeutics Files 8-K: Officer/Director Changes & Financials
Ticker: SPRO · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, financials
Related Tickers: SPRO
TL;DR
Spero Therapeutics (SPRO) filed an 8-K: board shakeup and financials released.
AI Summary
On April 22, 2025, Spero Therapeutics, Inc. filed an 8-K report detailing the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements. The filing also includes financial statements and exhibits, with the report being publicly filed on April 28, 2025.
Why It Matters
Changes in corporate leadership and the filing of financial statements can signal shifts in company strategy and financial health, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, coupled with financial statement filings, can indicate internal restructuring or financial performance that may affect the company's future prospects.
Key Numbers
- 001-38266 — SEC File Number (Identifies the company's filings with the SEC.)
- 46-4590683 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- April 22, 2025 (date) — Earliest event reported
- April 28, 2025 (date) — Filing date
- 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139 (address) — Principal executive offices
FAQ
What specific officer or director positions were affected by the departures?
The filing indicates the departure of 'certain officers' and 'certain directors' but does not specify the exact roles in the provided text.
Were any new directors or officers appointed?
Yes, the filing explicitly mentions the 'Election of Directors' and 'Appointment of Certain Officers'.
What is the nature of the 'Compensatory Arrangements' mentioned?
The filing notes 'Compensatory Arrangements of Certain Officers' but does not provide details on the specific arrangements in the provided text.
What financial statements are included in this filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific statements are not detailed in the provided text.
What is the primary business of Spero Therapeutics, Inc. according to the filing?
Spero Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 regarding Spero Therapeutics, Inc. (SPRO).